


Immune Checkpoint Inhibitors



Much of the recent advancement in the field of tumor immunology and immunotherapy has been generated by the recognition that immune checkpoint proteins can be blocked by human antibodies. Immune checkpoint pathways involve both costimulatory and inhibitory proteins. The costimulatory receptors transduce signals to promote immunity against pathogens. The inhibitory receptors, on the other hand, negatively regulate T-cell activation to prevent excessive inflammation. Immunomodulatory antibodies directed against cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1), have demonstrated significant promise in the treatment of melanoma and other tumor types.

These agents are commonly called “checkpoint inhibitors” because they block normally negative regulators of T cell immunity. Numerous other immune checkpoint pathways that could be the target of novel therapies have been identified and are currently under development for clinical testing. BioVision offers a comprehensive collection of immune checkpoint proteins and antibodies to support immune checkpoint blockade research. These products have demonstrated consistent and excellent performance in a variety of assays.

Immune Checkpoint Inhibitors

| Product Name | Cat. No. | Size | CAS No. |
|-------------------------------|----------|----------------|--------------|
| A77 1726 | 1973 | 5 mg, 25 mg | 108605-62-5 |
| Ascomycin | 1573 | 2 mg | 104987-12-4 |
| Azathioprine | 9536 | 100 mg, 500 mg | 446-86-6 |
| AZD-4635 | B2012 | 5 mg, 25 mg | 1321514-06-0 |
| Busulfan | B1063 | 1 g, 5 g | 55-98-1 |
| CPI-444 | B1970 | 5 mg, 25 mg | 1202402-40-1 |
| Cyclophosphamide monohydrate | 9657 | 1 g, 5 g | 6055-19-2 |
| Cyclosporine A | 1522 | 100 mg, 1 g | 59865-13-3 |
| Fingolimod (FTY-720A, FTY720) | 1618 | 5 mg, 25 mg | 162359-56-0 |
| FK-506 | 1563 | 1 mg, 10 mg | 104987-11-3 |
| GSK-J4 hydrochloride | 2259 | 1 mg, 5 mg | N/A |
| GW2580 | 1740 | 5 mg, 25 mg | 870483-87-7 |
| EZSolution™ GW2580 | 2549 | 5 mg | 870483-87-7 |
| IDO Pathway inhibitor | 2746 | 50 mg, 250 mg | 110117-83-4 |
| IDO1 Inhibitor I | 2745 | 5 mg, 25 mg | 914471-09-3 |
| INCB-024360 | 9477 | 5 mg, 25 mg | 1204669-58-8 |
| JZL195 | B1064 | 5 mg, 25 mg | 1210004-12-8 |

155 S. Milpitas Blvd, Milpitas, CA 95035

T: 408-493-1800 F: 408-493-1801

Toll Free: 800-891-9699 (US Only)

BioVision
BioVision Incorporated



Immune Checkpoint Inhibitors

| Product Name | Cat. No. | Size | CAS No. |
|--------------------------------|----------|---------------|--------------|
| Laquinimod | 2332 | 5 mg, 25 mg | 248282-07-7 |
| Leflunomide | 1972 | 10 mg, 50 mg | 75706-12-6 |
| Maraviroc | B2044 | 5 mg, 25 mg | 376348-65-1 |
| 6-Mercaptopurine (monohydrate) | B2039 | 50 mg, 250 mg | 50-44-2 |
| ML243 | 2515 | 5 mg, 25 mg | 1426576-80-8 |
| MX69 | B1568 | 5 mg, 25 mg | 1005264-47-0 |
| Mycophenolic Acid | 1882 | 50 mg, 250 mg | 24280-93-1 |
| Myriocin (ISP-1) | 2567 | 5 mg, 25 mg | 35891-70-4 |
| NLG919 | 9407 | 5 mg, 25 mg | 1402836-58-1 |
| PD-1/PD-L1 Inhibitor 1 | B1213 | 5 mg, 25 mg | 1675201-83-8 |
| PD-1/PD-L1 Inhibitor 2 | B1050 | 5 mg, 25 mg | 1675203-84-5 |
| Pomalidomide | B1811 | 5 mg, 25 mg | 19171-19-8 |
| (R,S)-Lenalidomide | 1862 | 25 mg, 100 mg | 191732-72-6 |
| EZSolution™ (R,S)-Lenalidomide | B1503 | 10 mg | 191732-72-6 |
| Rocaglamide | 1863 | 100 µg | 84573-16-0 |
| SCH-58261 | B1638 | 5 mg, 25 mg | 160098-96-4 |
| TAPI-0 | 2067 | 1 mg | 143457-40-3 |
| TAPI-1 | 2068 | 1 mg | 171235-71-5 |
| EZSolution™ TAPI-1 | 2537 | 1 mg | 171235-71-5 |
| TAPI-2 | 2069 | 1 mg | 187034-31-7 |
| Tasquinimod | B2855 | 5 mg, 25 mg | 254964-60-8 |
| (±)-Thalidomide | 2020 | 10 mg, 50 mg | 50-35-1 |
| Vidofludimus | B1633 | 5 mg, 25 mg | 717824-30-1 |
| Zotarolimus | 9530 | 1 mg, 5 mg | 221877-54-9 |

PD-L1 Binding Ligand

| Product Name | Cat. No. | Size | CAS No. |
|--------------|----------|--------------|---------|
| WL12 | B2586 | 500 µg, 1 mg | NA |

Please visit www.BioVision.com for a comprehensive overview on our products.